share_log

22nd Century Group to Participate in the Emerging Growth Virtual Conference on August 21, 2024

22nd Century Group to Participate in the Emerging Growth Virtual Conference on August 21, 2024

22世纪集团将于2024年8月21日参加新兴成长虚拟会议。
newsfile ·  08/20 17:52

Mocksville, North Carolina--(Newsfile Corp. - August 20, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced that it will provide a brief corporate update as part of the Emerging Growth Virtual Conference on Wednesday, August 21, 2024 at 4:25 PM Eastern Time.

北卡罗来纳州莫克斯维尔——(Newsfile Corp.——2024年8月20日)——22世纪集团公司(NASDAQ: XXII),一家专注于尼古丁危害减少和合同制造的烟草产品公司,今天宣布将在2024年8月21日星期三下午4:25美国东部时间作为新兴增长虚拟会议的一部分提供简要的企业更新。

To access the live presentation, please use the events link online at .

要获取实时演示,请使用在线事件链接。

About 22nd Century Group, Inc.
22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction by offering tobacco products with 95% less nicotine, designed to improve health and wellness by helping smokers smoke less. Backed by comprehensive and extensively patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, the Company has pioneered the development of high-yield, proprietary reduced nicotine content (RNC) tobacco plants and clinically validated RNC cigarette products. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of both its own products and contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.

关于22世纪集团公司
22世纪集团公司(NASDAQ: XXII)是一家农业生物技术公司,专注于通过提供含有95%少尼古丁的烟草产品,帮助吸烟者减少烟草危害,旨在通过帮助吸烟者减少吸烟来改善健康和福祉。公司拥有全面和广泛获得专利的技术来调节烟草植物中尼古丁生物合成活动,开创了高产量、专有的降低尼古丁含量(RNC)烟草植物和经临床验证的RNC香烟产品的发展。公司于2021年12月获得了首个、也是唯一一个可燃烟草风险改善烟草制品(MRTP)授权的FDA授权。公司是《和解协议》(“MSA”)下的后续参与制造商,并垂直整合了自己的产品和合同制造运营(“CMO”),主要包括品牌滤嘴雪茄和传统香烟的生产。

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

欲了解更多,请访问 xxiicentury.com,在Twitter、领英和YouTube上了解我们公司的最新动态。

Learn more about VLN at tryvln.com.

了解有关VLN的更多信息,请访问 tryvln.com。

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

投资者关系与媒体联系
Matt Kreps
投资者关系
22世纪集团
mkreps@xxiicentury.com
214-597-8200

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发